AU2014315124A1 - Methods and compositions for viral vectored vaccines - Google Patents

Methods and compositions for viral vectored vaccines Download PDF

Info

Publication number
AU2014315124A1
AU2014315124A1 AU2014315124A AU2014315124A AU2014315124A1 AU 2014315124 A1 AU2014315124 A1 AU 2014315124A1 AU 2014315124 A AU2014315124 A AU 2014315124A AU 2014315124 A AU2014315124 A AU 2014315124A AU 2014315124 A1 AU2014315124 A1 AU 2014315124A1
Authority
AU
Australia
Prior art keywords
vector
vaccine
animal
poly
iclc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014315124A
Other languages
English (en)
Inventor
De-Chu Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altimmune Inc
Original Assignee
Altimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altimmune Inc filed Critical Altimmune Inc
Publication of AU2014315124A1 publication Critical patent/AU2014315124A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
AU2014315124A 2013-09-06 2014-09-05 Methods and compositions for viral vectored vaccines Abandoned AU2014315124A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361874505P 2013-09-06 2013-09-06
US61/874,505 2013-09-06
PCT/US2014/054234 WO2015035128A1 (en) 2013-09-06 2014-09-05 Methods and compositions for viral vectored vaccines

Publications (1)

Publication Number Publication Date
AU2014315124A1 true AU2014315124A1 (en) 2016-04-07

Family

ID=52625855

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014315124A Abandoned AU2014315124A1 (en) 2013-09-06 2014-09-05 Methods and compositions for viral vectored vaccines

Country Status (8)

Country Link
US (1) US20150071964A1 (enExample)
EP (1) EP3041503A4 (enExample)
JP (1) JP2016529316A (enExample)
KR (1) KR20160049010A (enExample)
AU (1) AU2014315124A1 (enExample)
CA (1) CA2923406A1 (enExample)
MX (1) MX2016002823A (enExample)
WO (1) WO2015035128A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
EP3525763B1 (en) 2016-10-12 2025-03-05 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2020210149A1 (en) * 2019-04-06 2020-10-15 Altimmune Inc Broad and long-lasting influenza vaccine
JP2023522108A (ja) * 2020-04-20 2023-05-26 グレフェックス， インコーポレイテッド 広域反応性コロナウイルスワクチンのエンジニアリング並びに関連する設計及び使用
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2712673C2 (de) * 1977-03-23 1983-12-15 Krauss U. Reichert Gmbh + Co Kg Spezialmaschinenfabrik, 7012 Fellbach Stoßmessermaschine
US20030134815A1 (en) * 1991-08-20 2003-07-17 The Govt. Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Adenovirus mediated transfer of genes to the gastrointestinal tract
US20050271689A1 (en) * 2003-07-11 2005-12-08 Chun-Ming Huang Novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax
AU2003248791A1 (en) * 2002-07-03 2005-11-09 Oncovir, Inc. Method for preparation of poly-iclc and uses thereof
US8592391B2 (en) * 2003-07-01 2013-11-26 Andres Salazar Method for therapeutic, clinical and veterinary use poly-ICLC
US7834064B2 (en) * 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
CN101248186A (zh) * 2005-05-23 2008-08-20 瓦克辛公司 不含腺病毒的重组腺病毒载体的快速生产
US20070178115A1 (en) * 2005-08-15 2007-08-02 Tang De-Chu C Immunization of avians by administration of non-replicating vectored vaccines
PT1996238T (pt) * 2006-02-28 2016-07-11 Vaxart Inc Vetores adenovíricos quiméricos e arncd como agonista de tlr3
CN102056622B (zh) * 2008-06-05 2016-04-06 免疫疫苗技术有限公司 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
JP2012504140A (ja) * 2008-09-26 2012-02-16 オーバーン・ユニバーシティ 非複製性ベクターワクチンの粘膜投与による鳥類の免疫処置
AU2010232180B2 (en) * 2009-03-31 2016-09-22 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
WO2010142017A1 (en) * 2009-06-09 2010-12-16 Defyrus, Inc . Administration of interferon for prophylaxis against or treatment of pathogenic infection
KR20200008014A (ko) * 2011-03-21 2020-01-22 알티뮨 인크. 급속 및 지속적 면역학적제제-치료제

Also Published As

Publication number Publication date
US20150071964A1 (en) 2015-03-12
CA2923406A1 (en) 2015-03-12
EP3041503A4 (en) 2017-06-07
WO2015035128A1 (en) 2015-03-12
EP3041503A1 (en) 2016-07-13
KR20160049010A (ko) 2016-05-04
MX2016002823A (es) 2016-12-16
JP2016529316A (ja) 2016-09-23

Similar Documents

Publication Publication Date Title
JP6943908B2 (ja) 迅速かつ持続的な免疫学的治療法
US11141477B2 (en) Rapid and prolonged immunologic-therapeutic
US20150071964A1 (en) Methods and compositions for viral vectored vaccines
KR20110081222A (ko) 비복제성 벡터화된 백신의 점막 투여에 의한 조류의 면역화
Xu et al. Evaluation of a chimeric multi-epitope-based DNA vaccine against subgroup J avian leukosis virus in chickens
Toro et al. Avian Influenza Vaccination in Chickens and Pigs with Replication-Competent Adenovirus–Free Human Recombinant Adenovirus 5
US8541167B2 (en) Methods and compositions for vaccination
Rhee et al. Translational Mini-Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development
CA3243646A1 (en) 7DW8-5 TREATMENT FOR COVID-19 AND OTHER VIRUS-INDUCED RESPIRATORY INFECTIONS
Haroldo ToroA et al. Avian Influenza Vaccination in Chickens and Pigs with Replication-Competent Adenovirus–Free Human Recombinant Adenovirus 5

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted